The Next Wave of Obesity Drugs: What's Actually Coming After Wegovy and Zepbound

A year ago, "the next wave of obesity drugs" was a slide in a biotech deck. As of April 2026, it's a stack of real filings, Phase 3 readouts, and dosing schedules your endocrinologist can already pronounce. Five names keep surfacing whenever patients ask what comes after Wegovy and Zepbound: CagriSema, retatrutide, amycretin, survodutide, and MariTide.

The ceiling is moving. Zepbound sits at 20.9% mean body weight loss today. One of the five — retatrutide — has a plausible shot at pushing that past 25%. None of them are FDA-approved yet. And the gap between a press release and a prescription pad runs 12 to 24 months in a good year.

What each one delivers on paper, what it's trying to beat, and which country's patients will reach for it first — that's the map worth having.

The current ceiling, plainly stated

Three drugs define what a U.S. physician can prescribe today for weight management.

• Wegovy (semaglutide 2.4 mg) — STEP 1 reported 14.9% mean body weight reduction at 68 weeks.
• Zepbound (tirzepatide 15 mg) — SURMOUNT-1 reported 20.9% at 72 weeks. Highest number for any approved obesity drug.
• Foundayo (orforglipron) — the first oral once-daily GLP-1 for obesity. FDA-approved on April 1, 2026. Roughly 14–15% at 72 weeks, $149/month cash list through LillyDirect. Our deep dive on Foundayo covers the access story in full.

Saxenda (liraglutide, daily injection) still exists — roughly 8% at 56 weeks — but no one reaches for it in 2026 unless there's a specific reason like pediatric use.

So the bar for any pipeline drug is narrow. Beat 20.9%. Or offer a route Zepbound can't — oral, monthly, liver-targeted. Or open a label Zepbound doesn't yet carry. Miss all three and the market yawns.

The benchmark isn't Wegovy anymore. It's Zepbound at 20.9%. A drug that can't clear that number at a comparable price doesn't reshape anything.

CagriSema: Novo Nordisk's counter-move

CagriSema pairs cagrilintide — a long-acting amylin analog — with semaglutide, the molecule behind Wegovy. One weekly subcutaneous pen, two appetite pathways.

Top-line REDEFINE-1, reported December 20, 2024: 22.7% mean body weight reduction at 68 weeks across 3,417 adults with obesity, versus 2.3% on placebo. Novo had been signaling something closer to 25%, which is why 22.7% landed as a disappointment on the day — even though it's numerically above Zepbound's 20.9%. REDEFINE-2, in people with type 2 diabetes and obesity, came in at 15.7% at 68 weeks (reported March 8, 2026). REDEFINE-3, the cardiovascular outcomes arm, is still running with interim data guided for 2027.

Novo has flagged a regulatory submission in the first half of 2026. A realistic FDA decision lands late 2026 or early 2027.

The patient question is narrower than the pharma framing: does a 22.7% combo actually feel different from a 20.9% tirzepatide at roughly the same $1,000–$1,400 monthly list? Amylin works through a distinct pathway, and interim reads hint at less GI nausea. Head-to-head data doesn't exist yet. For now, CagriSema reads as a serious reply to Zepbound — not a clean leap past it.

Retatrutide — the 30% question

Lilly's next act after tirzepatide hits three receptors instead of two. GLP-1. GIP. Glucagon. That third arm is the interesting one — glucagon nudges energy expenditure up while the other two suppress appetite and sharpen insulin signaling.

Phase 2 TRIUMPH data, published in the New England Journal of Medicine in June 2023, reported 24.2% mean body weight reduction at 48 weeks on the 12 mg dose. Phase 2 numbers usually shrink in Phase 3. Even so, retatrutide is the first obesity drug with a credible shot at a mean loss above 30% at higher doses and longer durations.

The Phase 3 package is unusually wide — TRIUMPH-1 through TRIUMPH-5, covering obesity, type 2 diabetes, obstructive sleep apnea, knee osteoarthritis, and cardiovascular outcomes. TRIUMPH-1 (adults with obesity) is guided for topline in late 2026. A Phase 2 MASH arm showed an 8.7 percentage-point resolution advantage over placebo at 24 weeks — part of why Lilly is threading this drug through more than one label.

Realistic FDA submission: 2026–2027. Realistic approval: 2027 at the earliest. If retatrutide holds its Phase 2 magnitude, it won't just pass Zepbound. It'll redraw what a meaningful response looks like.

Two routes, one molecule: amycretin

Novo's other bet is structurally different from CagriSema. Instead of two drugs in one pen, amycretin is a single molecule that acts as a dual agonist at both GLP-1 and amylin receptors. Cleaner biology. Cleaner manufacturing.

What makes it interesting isn't just the receptor profile — it's the delivery. Novo is running both an oral tablet and a subcutaneous injection in parallel. The oral Phase 1 at 50 mg reported 13.1% mean body weight reduction at 12 weeks. The subcutaneous Phase 1b reported 22.0% at 36 weeks on the highest dose. Both numbers are unusually strong for trials that early, at lengths where most weight curves are nowhere near flat.

Phase 2 readouts are staggered across 2026. As of April 2026, Phase 3 hasn't started. A realistic approval window is 2028 or later.

The reason amycretin matters already: if the oral formulation holds up at scale, it becomes a direct challenger to Foundayo and a longer-term threat to injectable tirzepatide. An oral, amylin-inclusive option lets patients stay GLP-1-adjacent without a needle — and, depending on price, at a very different monthly cost.

Survodutide and the liver story

A once-weekly GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma. Phase 2 in obesity showed 18.7% mean body weight reduction at 46 weeks on the highest dose (2024). Respectable — but not the number that makes this drug distinctive.

The liver is where survodutide changes the conversation. In a separate Phase 2 trial in MASH (metabolic dysfunction-associated steatohepatitis), up to 83% of participants on the highest dose achieved histological MASH improvement. Most MASH-only drugs would take a victory lap over that. The FDA granted survodutide an expedited-review designation in MASH in 2024 — the kind of status reserved for serious unmet need.

Phase 3 SYNCHRONIZE in obesity is ongoing. Plausible FDA filings: 2026–2027 in obesity, 2027 or later in MASH.

For someone living with obesity and fatty liver disease — a shockingly common pairing — this is the one drug in the group that can credibly be prescribed as a single story instead of two parallel ones. That's why survodutide matters despite a weight-loss number below CagriSema's and well below retatrutide's.

MariTide: twelve shots a year

Amgen's maridebart cafraglutide is the outlier. A peptide-antibody conjugate that combines GIP receptor antagonism with GLP-1 agonism — and, because of its molecular structure, supports monthly subcutaneous dosing instead of weekly.

Phase 2 topline, reported November 2024: up to 20.0% mean body weight reduction at 52 weeks on the highest dose, with the weight curve still trending downward at week 52. The plateau hadn't arrived. Phase 3 MARITIME began enrolling in early 2026.

Realistic approval window: 2028 at the earliest.

Watch this drug for one reason — adherence. Weekly-injection GLP-1 retention at 12 months is ugly in real-world U.S. data (roughly 50–70% of commercially insured patients stop Wegovy or Zepbound within a year). Twelve injections a year instead of fifty-two changes the math on long-term weight maintenance in a way a bigger trial number alone never could.

A drug that doesn't get taken doesn't work. MariTide's real bet isn't a bigger weight-loss number — it's a smaller number of injections.

Side-by-side, compressed

One table, one row per drug. "Best reported loss" uses the strongest published number to date, so amycretin's early-phase figures should be read as preliminary.

Against the current ceiling — Wegovy 14.9%, Zepbound 20.9% — every drug in that table clears Wegovy. Two plausibly clear Zepbound today. Only one (retatrutide) has a real chance of resetting the ceiling entirely. The rest compete on route, liver data, or dosing frequency.

Who sees what, and when

Approval timing splinters by country. That's the part most English-language pipeline coverage glosses over. The FDA is almost certainly first for CagriSema. Other regulators typically lag 12 to 24 months behind for GLP-1 obesity approvals — assuming the Phase 3 data holds. (All of this is as of April 2026 and subject to any regulatory delay.)

A few country-specific things worth flagging:

• Korea. Zepbound isn't sold under that brand name. Tirzepatide is Mounjaro (T2D label), used off-label for weight — a dedicated obesity indication path remains open. The Mounjaro pricing breakdown in Korean covers the cost structure.
• Japan. Mounjaro is approved only for type 2 diabetes as of April 2026 — no obesity label yet. That lag is exactly why CagriSema would land harder in Japan than in the U.S., where Zepbound is already on shelves.
• China. The semaglutide obesity indication (诺和盈) went live in June 2024. Tirzepatide's obesity application sits under NMPA review. So for now, 诺和盈 is the only on-label obesity shot on the mainland — and CagriSema arrives into that vacuum, not a crowded market.
• Spain and France (AEMPS / ANSM). Both track the EMA timeline. Mounjaro's 2024 EU obesity label took about nine months after the initial EMA opinion to reach full national reimbursement debates. Expect a similar rhythm for CagriSema.

There's an uncomfortable pattern in all this: the U.S. gets new obesity drugs first, pays the highest list price, and then watches other markets either approve more slowly or negotiate harder. Early access, expensive access. Outside the U.S., it means another year of watching Reddit threads about a drug you can't fill yet.

If you're on Wegovy or Zepbound right now

A few things worth sitting with before the next doctor visit.

• None of the five pipeline drugs are approved for concurrent use with Wegovy, Zepbound, Mounjaro, or Foundayo. Stacking GLP-1s isn't a casual decision, and no trial has tested it.
• A 22.7% mean is just that — a mean. Some patients lost much more, some much less. Trial distributions matter as much as headline averages.
• Real-world adherence erodes trial numbers. If you stopped Zepbound at month four because of nausea, a drug with a harder titration ladder won't save you. A monthly-dosing drug like MariTide might — if adherence is your actual problem.
• Regulatory timing is never certain. A soft Phase 3 readout can push approval back a year. A positive outcomes trial (REDEFINE-3 is the one to watch) can pull it forward. "Late 2026" and "2027" are best guesses, not deadlines.
• Outside the U.S., the planning horizon is usually 12 to 24 months longer than the FDA timeline. Factor that into any decision about stopping a drug you currently have access to.

If a new pipeline drug doesn't open a door you can't already open with Wegovy, Zepbound, or Foundayo, waiting six months for cleaner data usually beats switching on headlines.

Our semaglutide versus tirzepatide global comparison walks through current-generation choices in more depth. For the narrower question of which leader to start on, the Wegovy vs. Mounjaro breakdown is the cleaner starting point.

What 2026 and 2027 probably look like

Four beats, in a likely order:

1. CagriSema is filed in the first half of 2026 and becomes the first post-Zepbound obesity drug to reach an FDA decision — late 2026 or early 2027.
2. Retatrutide's TRIUMPH-1 reads out in late 2026. If the Phase 2 magnitude holds, the ceiling resets from 20.9% toward something in the high 20s.
3. Survodutide files for MASH first, obesity second, and becomes the unusual case of a weight-loss drug whose liver data ends up more commercially interesting than its weight number.
4. Amycretin and MariTide stay in the "worth watching" column through 2026, with Phase 3 readouts the real decision points in 2027 and beyond.

None of this is on your pharmacy shelf today. All of it is close enough that starting a GLP-1 in 2026 is a different decision than it was in 2023 — because what you're starting is no longer the final available product. It's a bridge to something that's very likely better on at least one axis you care about: raw weight loss, oral availability, injection frequency, or a co-occurring condition like fatty liver disease.

If you're talking to your doctor this month about starting, switching, or stopping a GLP-1, the pipeline is worth bringing up by name. Not because any of these drugs are prescribable yet — but because the right timeline question isn't "what's best today?" It's "what do I want to be on in 18 months, and what does that mean for my next step?" Worth putting on the table at your next refill visit.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app